Call Boomerang Books 1300 36 33 32

mother's dayMother's Day is Sunday 13 May. Our Gift Guide is the best place to get gifts for Mum. Visit the Gift Guide Now...

Description - Strategies for Organic Drug Synthesis and Design by Daniel Lednicer

This book examines and evaluates the strategies utilized to design and synthesize pharmaceutically active agents. Significant updates over the last 10 years since the publication of the 1st edition include synthesis of enantiomerically pure isomers, novel chemical methodologies, and new pharmaceutical agents targeted at novel biological endpoints. Written by an experienced successful author, this book meets the needs of a growing community of researchers in pharmaceutical R &D, as well as medical professionals, by providing a useful guide for designing and synthesizing pharmaceutical agents. Additionally, it is a useful text for medicinal chemistry students.

Buy Strategies for Organic Drug Synthesis and Design by Daniel Lednicer from Australia's Online Independent Bookstore, Boomerang Books.

Book Details

ISBN: 9780470190395
ISBN-10: 0470190396
Format: Hardback
(231mm x 163mm x 40mm)
Pages: 682
Imprint: Wiley-Blackwell
Publisher: John Wiley and Sons Ltd
Publish Date: 1-Nov-2008
Country of Publication: United States

Other Editions - Strategies for Organic Drug Synthesis and Design by Daniel Lednicer

Book Reviews - Strategies for Organic Drug Synthesis and Design by Daniel Lednicer

» Have you read this book? We'd like to know what you think about it - write a review about Strategies for Organic Drug Synthesis and Design book by Daniel Lednicer and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a Boomerang Books Account Holder - it's free to sign up and there are great benefits!)

Write Review


Author Biography - Daniel Lednicer

Daniel Lednicer, PhD , is the acclaimed author of several books on drug synthesis and discovery. His career has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. He has also served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.